Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial
International Clinical Psychopharmacology Jan 31, 2018
Morabbi MJ, et al. - In this work, researchers assessed the efficacy of pexacerfont, a CRF1 antagonist, for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence. Findings suggested that pexacerfont has a potential for the treatment of withdrawal from drug dependence.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries